The key is ensuring that your body is not currently struggling with the common side effects of GLP-1 therapy, such as dehydration or nausea
Initial consultation and lab work add to the upfront cost
Please read the entire Disclaimer carefully before you use this website or read the newsletter
doi: 10.1080/1744666X.2021.1971973 143 WanderPLLowyEBesteLATulloch-PalominoLKorpakAet al
When discussing semaglutide, naltrexone, or combination therapy with your provider, sharing your genetic predisposition context can support a more personalized conversation about which metabolic pathways may be most relevant to your situation
[80] Trials for cardiovascular health [edit] In March 2024, the US Food and Drug Administration expanded the indication for semaglutide (brand name Wegovy) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and who are either obese or overweight